查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423334

醫院獲得性疾病檢測市場報告（依適應症分類）（UTI（泌尿道感染）、SSI（手術部位感染）、肺炎、血流感染、MRSA（抗甲氧西林金黃色葡萄球菌）等）及地區2024 -2032

Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2023年，全球醫院獲得性疾病檢測市場規模達到121億美元。展望未來， IMARC Group預計到2032年該市場將達到466億美元，2024-2032年複合年成長率（CAGR）為15.6%。

院內感染 (HAI) 或醫院感染是在醫院和醫療診所獲得的疾病。院內感染是指源自醫院的感染或疾病。即使在療養院、復健中心、醫院或任何其他臨床環境附近，一個人也可能患上此類疾病。大多數人在加護病房 (ICU) 和急診室 (ER) 時都會罹患 HAI。一般來說，這些疾病的潛伏期為入院後48小時至4天不等。醫院獲得性疾病的一個主要原因是醫院內部工作人員缺乏適當的衛生習慣。其他原因可能包括維護程度低於標準、醫院工作人員的自滿情緒以及多重抗藥性微生物 (MDRO) 的增加。一些最常見的院內感染包括肺炎、原發性血流感染、泌尿道感染等。在許多情況下，也發現這些院內感染有時可追溯到患者自身的微生物組。當保護性皮膚層接觸到可能的威脅並導致感染時，尤其是在外科手術後，就會發生這種情況。

市場走向：

在人口成長和醫療基礎設施現代化的推動下，全球醫療保健設施的數量大幅增加。這導致醫院感染發病率上升，推動了醫院獲得性疾病檢測的需求。此外，隨著先進技術和科學創新，市場上現在有各種用於預防、診斷和監測 HAI 的技術，如微陣列、聚合酶鏈反應 (PCR)、即時定位系統 (RTLS) 和固相雜交。 RTLS 等技術可以輕鬆防止 HAI 在患者和工作人員中傳播。患者對醫院感染的認知不斷提高，以及政府頒布法規對醫院感染發生率高的醫院進行處罰，這些都是促進市場成長的其他因素。

本報告回答的關鍵問題

  • 2023年全球醫院獲得性疾病檢測市場規模有多大？
  • 2024-2032 年全球醫院獲得性疾病檢測市場成長率為何？
  • 全球醫院獲得性疾病檢測市場的促進因素是什麼？
  • 全球醫院獲得性疾病檢測市場的主要行業趨勢是什麼？
  • COVID-19對全球醫院獲得性疾病檢測市場有何影響？
  • 全球醫院獲得性疾病檢測市場依適應症分類是怎樣的？
  • 全球醫院獲得性疾病檢測市場主要有哪些地區？
  • 全球醫院獲得性疾病檢測市場的主要公司/參與者有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球醫院獲得性疾病檢測市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場區隔：依指標
  • 市場區隔：按地區
  • 市場預測
  • SWOT分析
    • 概述
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • 價值鏈分析
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅
  • 價格分析

第 6 章：市場區隔：依跡象

  • UTI（泌尿道感染）
    • 市場走向
    • 市場預測
  • SSI（手術部位感染）
    • 市場走向
    • 市場預測
  • 肺炎
    • 市場走向
    • 市場預測
  • 血流感染
    • 市場走向
    • 市場預測
  • MRSA（抗甲氧西林金黃色葡萄球菌）
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：按地區

  • 北美洲
    • 市場走向
    • 市場預測
  • 歐洲
    • 市場走向
    • 市場預測
  • 亞太地區
    • 市場走向
    • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場預測
  • 拉丁美洲
    • 市場走向
    • 市場預測

第 8 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Alere, Inc.
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • QIAGEN
    • Siemens Healthcare
    • Diatherix Laboratories, Inc.
    • Meridian Bioscience, Inc.
    • Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
    • Cepheid, Inc.
Product Code: SR112024A1128

Abstract

The global hospital acquired disease testing market size reached US$ 12.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 46.6 Billion by 2032, exhibiting a growth rate (CAGR) of 15.6% during 2024-2032.

Hospital-acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital-acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Other reasons can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patient's own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

Market Trends:

Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital acquired disease testing market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on indication.

Breakup by Indication:

UTI (Urinary Tract Infection)

SSI (Surgical Site Infection)

Pneumonia

Bloodstream Infections

MRSA (Methicillin-Resistant Staphylococcus Aureus)

Others

Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.

Regional Insights:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Competitive Landscape:

The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMerieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.

This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.

Key Questions Answered in This Report

  • 1. What is the market size for the global hospital acquired disease testing market 2023?
  • 2. What is the global hospital acquired disease testing market growth 2024-2032?
  • 3. What are the global hospital acquired disease testing market drivers?
  • 4. What are the key industry trends in the global hospital acquired disease testing market?
  • 5. What is the impact of COVID-19 on the global hospital acquired disease testing market?
  • 6. What is the global hospital acquired disease testing market breakup by indication?
  • 7. What are the major regions in the global hospital acquired disease testing market?
  • 8. Who are the key companies/players in the global hospital acquired disease testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Acquired Disease Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Indication
  • 5.5 Market Breakup by Region
  • 5.6 Market Forecast
  • 5.7 SWOT Analysis
    • 5.7.1 Overview
    • 5.7.2 Strengths
    • 5.7.3 Weaknesses
    • 5.7.4 Opportunities
    • 5.7.5 Threats
  • 5.8 Value Chain Analysis
  • 5.9 Porters Five Forces Analysis
    • 5.9.1 Overview
    • 5.9.2 Bargaining Power of Buyers
    • 5.9.3 Bargaining Power of Suppliers
    • 5.9.4 Degree of Competition
    • 5.9.5 Threat of New Entrants
    • 5.9.6 Threat of Substitutes
  • 5.10 Price Analysis

6 Market Breakup by Indication

  • 6.1 UTI (Urinary Tract Infection)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 SSI (Surgical Site Infection)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Pneumonia
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Bloodstream Infections
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Europe
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Asia Pacific
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Middle East and Africa
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Latin America
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Key Players
  • 8.3 Profiles of Key Players
    • 8.3.1 Abbott Laboratories
    • 8.3.2 Alere, Inc.
    • 8.3.3 Becton, Dickinson and Company
    • 8.3.4 bioMerieux SA
    • 8.3.5 F. Hoffmann-La Roche Ltd.
    • 8.3.6 Hologic, Inc.
    • 8.3.7 QIAGEN
    • 8.3.8 Siemens Healthcare
    • 8.3.9 Diatherix Laboratories, Inc.
    • 8.3.10 Meridian Bioscience, Inc.
    • 8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
    • 8.3.12 Cepheid, Inc.

List of Figures

  • Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2023
  • Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2023
  • Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
  • Figure 7: Global: Hospital Acquired Disease Testing Industry: Value Chain Analysis
  • Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter's Five Forces Analysis
  • Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
  • Table 5: Global: Hospital Acquired Disease Testing Market: Key Players